TLDR:  Fogo cancels $20M token presale, distributing 2% of tokens via airdrop instead. Fogo Flames points program rewards early testnet users and bridge participantsTLDR:  Fogo cancels $20M token presale, distributing 2% of tokens via airdrop instead. Fogo Flames points program rewards early testnet users and bridge participants

Solana VM Blockchain Fogo Cancels $20M Token Sale, Opts for Airdrop

2025/12/14 18:41
3 min read

TLDR: 

  • Fogo cancels $20M token presale, distributing 2% of tokens via airdrop instead.
  • Fogo Flames points program rewards early testnet users and bridge participants.
  • Core contributors receive 34% of tokens locked, while community owns 11.25%.
  • Solana VM blockchain targets 40ms block times and 1,000+ TPS on testnet.

Fogo, an experimental Solana VM blockchain, has canceled its planned $20 million token presale ahead of its January mainnet launch. 

The project will now distribute tokens through an airdrop targeting early adopters and participants in its Fogo Flames points program. The decision emphasizes rewarding community members who contributed during the testnet phase.

The cancellation follows a recent 2% burn of Fogo’s initial token supply, permanently reducing the total supply. 

The airdrop will allocate the same 2% of tokens originally reserved for the presale to loyal supporters. The mainnet launch is scheduled for January 13, when the first rewards will be redeemable.

Fogo Airdrop and Token Distribution Plan

Fogo’s airdrop program will reward Fogo Fishers, Portal Bridge users, and early USDC bridge participants. 

The team stated on X, “We have taken a snapshot of Fogo Fishers, Portal Bridge points holders, and all USDC transfers since the initial presale announcement.” Tokens will be redeemable after the mainnet launch, reflecting the project’s commitment to early community support.

The project’s tokenomics reveal that 6.6% of tokens are allocated for immediately tradable airdrops. 

Core contributors receive 34% of tokens locked under a four-year vesting schedule, while the Fogo Foundation controls about one-third of the initial supply. Institutional investors such as Distributed Global and CMS Holdings hold 8.77%, and advisors receive 7%.

In addition, 11.25% of Fogo’s tokens were allocated to community ownership through prior Echo crowdfunding sales. 

By distributing tokens via airdrop rather than presale, the blockchain ensures broad and fair participation. The Fogo Flames points program remains central to distributing tokens to developers, community members, and ecosystem participants.

Technical Features and Network Development

Fogo operates on the Solana VM, targeting 40-millisecond block times and over 1,000 transactions per second on its testnet. 

The blockchain will integrate Jump Crypto’s validator client software, a first for any network. This integration aims to reduce malicious MEV while supporting real-time trade execution.

The Layer 1 blockchain is designed to support developers and community members while maintaining high efficiency and network reliability. 

Fogo’s airdrop strategy aligns token distribution with active participation in the ecosystem, encouraging users to engage before the public mainnet launch.

By focusing on airdrops, Fogo shifts away from traditional presales, rewarding early supporters and ensuring meaningful token distribution for its community.

The post Solana VM Blockchain Fogo Cancels $20M Token Sale, Opts for Airdrop appeared first on Blockonomi.

Market Opportunity
TokenFi Logo
TokenFi Price(TOKEN)
$0.003233
$0.003233$0.003233
-0.58%
USD
TokenFi (TOKEN) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26